Nia has over 10 years of experience working in the field of cell therapy in both academic and industry settings. He has expertise in developing CAR/TCR therapies and is experienced with both conventional and unconventional T-cells.

 

Prior to joining Bastion Therapeutics, Nia served as AD - Product Research at Quell Therapeutics developing autologous and allogeneic CAR-Treg therapies for solid organ transplantation, autoimmune and inflammatory diseases. Before that, he served as AD - Preclinical Development at Gadeta focusing on the development of γδ TCR-T therapies for haematological malignancies and solid tumours.

 

Nia completed his postdoctoral work on CAR T-cell therapies for solid tumours at King’s College London under Dr. Sophie Papa. He holds a PhD in Immunology from the Barts Cancer Institute at Queen Mary University of London.